E-course: New perspectives on antibody-drug conjugates as targeted therapy: From basics to clinical practice
Antibody-drug conjugates (ADCs) have the potential to improve targeted therapies in urological oncology. This e-course, organised by the European School of Urology and the EAU Sections of Urological Research and Oncological Urology, will explore the latest advancements in ADCs: from basic science, molecular targets, to clinical applications.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
The experts will discuss the role of ADCs in urological malignancies with a special focus on urothelial cancer, particularly those targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), providing insights into their potential to enhance treatment precision.
Speakers:
- Dr. G. Gandaglia (IT)
- Prof. C. Jeronimo (PT)
- Dr. D. Raggi (GB)
- Prof. J. Bellmunt (US)
This e-course is brought to you in collaboration with the EAU Sections of Urological Research and Oncological Urology.